Findings support clesrovimab as option to protect children entering second RSV season

Clesrovimab was well-tolerated among children entering their second respiratory disease season, according to the latest results from the phase 3 SMART trial.The findings indicate that the long-acting monoclonal antibody (mAb) could be another option to protect kids against respiratory syncytial virus in their second season.